Credit Suisse’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $19.3M | Sell |
129,346
-46,630
| -26% | -$7.78M | 0.02% | 642 |
|
|
2023
Q4 | $33.7M | Buy |
175,976
+10,564
| +6% | +$1.8M | 0.03% | 503 |
|
|
2023
Q3 | $29.3M | Sell |
165,412
-2,724
| -2% | -$520K | 0.03% | 532 |
|
|
2023
Q2 | $31.9M | Buy |
168,136
+36,063
| +27% | +$7.15M | 0.03% | 533 |
|
|
2023
Q1 | $26.5M | Buy |
132,073
+5,994
| +5% | +$1.26M | 0.03% | 590 |
|
|
2022
Q4 | $30M | Buy |
126,079
+12,570
| +11% | +$2.68M | 0.03% | 558 |
|
|
2022
Q3 | $22.7M | Sell |
113,509
-1,184
| -1% | -$226K | 0.03% | 620 |
|
|
2022
Q2 | $16.7M | Sell |
114,693
-4,917
| -4% | -$698K | 0.02% | 751 |
|
|
2022
Q1 | $19.5M | Buy |
119,610
+6,071
| +5% | +$925K | 0.02% | 781 |
|
|
2021
Q4 | $19.3M | Sell |
113,539
-44,147
| -28% | -$8.21M | 0.01% | 1107 |
|
|
2021
Q3 | $29.8M | Sell |
157,686
-27,625
| -15% | -$5.18M | 0.02% | 889 |
|
|
2021
Q2 | $31.4M | Sell |
185,311
-41,886
| -18% | -$6.13M | 0.02% | 918 |
|
|
2021
Q1 | $32.1M | Buy |
227,197
+52,963
| +30% | +$7.97M | 0.02% | 915 |
|
|
2020
Q4 | $22.6M | Buy |
174,234
+12,820
| +8% | +$1.71M | 0.01% | 1100 |
|
|
2020
Q3 | $23.5M | Sell |
161,414
-5,828
| -3% | -$828K | 0.01% | 949 |
|
|
2020
Q2 | $24.8M | Sell |
167,242
-42,555
| -20% | -$5.74M | 0.02% | 842 |
|
|
2020
Q1 | $22.8M | Buy |
209,797
+35,051
| +20% | +$4.05M | 0.02% | 773 |
|
|
2019
Q4 | $20.1M | Sell |
174,746
-17,896
| -9% | -$1.78M | 0.01% | 1017 |
|
|
2019
Q3 | $15.5M | Sell |
192,642
-99,736
| -34% | -$7.89M | 0.01% | 1069 |
|
|
2019
Q2 | $21.2M | Buy |
292,378
+10,046
| +4% | +$771K | 0.02% | 893 |
|
|
2019
Q1 | $26.4M | Sell |
282,332
-7,913
| -3% | -$662K | 0.02% | 716 |
|
|
2018
Q4 | $21.2M | Buy |
290,245
+42,054
| +17% | +$3.23M | 0.02% | 765 |
|
|
2018
Q3 | $21.7M | Buy |
248,191
+34,302
| +16% | +$3.45M | 0.02% | 826 |
|
|
2018
Q2 | $21.1M | Sell |
213,889
-98,641
| -32% | -$9.78M | 0.02% | 819 |
|
|
2018
Q1 | $37.2M | Buy |
312,530
+86,693
| +38% | +$11.2M | 0.03% | 552 |
|
|
2017
Q4 | $28.7M | Buy |
225,837
+66,911
| +42% | +$8.41M | 0.03% | 679 |
|
|
2017
Q3 | $18.7M | Sell |
158,926
-21,817
| -12% | -$1.86M | 0.02% | 876 |
|
|
2017
Q2 | $14.4M | Sell |
180,743
-67,621
| -27% | -$4.32M | 0.01% | 993 |
|
|
2017
Q1 | $12.7M | Buy |
248,364
+69,697
| +39% | +$3.22M | 0.01% | 1080 |
|
|
2016
Q4 | $6.69M | Sell |
178,667
-40,003
| -18% | -$1.67M | 0.01% | 1454 |
|
|
2016
Q3 | $14.8M | Buy |
218,670
+9,375
| +4% | +$661K | 0.01% | 982 |
|
|
2016
Q2 | $11.6M | Sell |
209,295
-25,173
| -11% | -$1.59M | 0.01% | 1062 |
|
|
2016
Q1 | $14.7M | Buy |
234,468
+44,957
| +24% | +$2.99M | 0.02% | 881 |
|
|
2015
Q4 | $17.8M | Sell |
189,511
-17,580
| -8% | -$1.63M | 0.02% | 841 |
|
|
2015
Q3 | $16.6M | Sell |
207,091
-102,839
| -33% | -$11.4M | 0.02% | 848 |
|
|
2015
Q2 | $37.2M | Buy |
309,930
+37,976
| +14% | +$4.54M | 0.04% | 550 |
|
|
2015
Q1 | $28.4M | Buy |
271,954
+22,482
| +9% | +$2.28M | 0.03% | 657 |
|
|
2014
Q4 | $24.2M | Buy |
249,472
+77,754
| +45% | +$7.2M | 0.02% | 776 |
|
|
2014
Q3 | $13.4M | Sell |
171,718
-24,846
| -13% | -$1.6M | 0.01% | 1130 |
|
|
2014
Q2 | $12.4M | Buy |
196,564
+47,586
| +32% | +$2.83M | 0.01% | 1238 |
|
|
2014
Q1 | $10M | Buy |
148,978
+26,967
| +22% | +$2.09M | 0.01% | 1258 |
|
|
2013
Q4 | $7.84M | Buy |
122,011
+25,608
| +27% | +$1.53M | 0.01% | 1457 |
|
|
2013
Q3 | $6.17M | Sell |
96,403
-21,126
| -18% | -$1.05M | 0.01% | 1473 |
|
|
2013
Q2 | $3.64M | Buy |
+117,529
| New | +$3.13M | ﹤0.01% | 1836 |
|
Other funds holding ALNY
Credit Suisse's ALNY Position: Q1 2024 in Review
Credit Suisse reduced its Alnylam Pharmaceuticals (ALNY) stake by 26% in Q1 2024, selling an estimated $7.78M and leaving 129,346 shares worth $19.3M. The position accounts for 0.02% of the portfolio, ranked #642.
Credit Suisse first reported a position in ALNY in Q2 2013 and has held it in 44 quarters since. The position peaked at $37.2M in Q1 2018. 498 funds tracked by Wall St. Rank hold ALNY as of Q1 2024.
- Credit Suisse held 129,346 shares of Alnylam Pharmaceuticals worth $19.3M as of Q1 2024.
- Credit Suisse sold 46,630 Alnylam Pharmaceuticals shares in Q1 2024, an estimated $7.78M.
- Alnylam Pharmaceuticals made up 0.02% of Credit Suisse's portfolio in Q1 2024, its #642 holding.
- Credit Suisse first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
- Credit Suisse's Alnylam Pharmaceuticals position peaked at $37.2M in Q1 2018.
- 498 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.